Comparative Pharmacology
Head-to-head clinical analysis: MAOLATE versus NORFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAOLATE versus NORFLEX.
MAOLATE vs NORFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MAOLATE is a centrally acting muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is not fully understood, but it is thought to act via inhibition of polysynaptic reflexes at the spinal level and possibly through sedation.
Orphenadrine is a centrally acting skeletal muscle relaxant with anticholinergic and local anesthetic properties. It acts primarily by blocking cholinergic receptors in the central nervous system, particularly in the reticular activating system, leading to reduced muscle spasm and rigidity.
250 mg orally 4 times daily or 500 mg orally 3 times daily for 21 days; maximum daily dose 2000 mg.
Adults: 100 mg orally twice daily. Maximum dose: 200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment, up to 20-30 hours in severe renal failure; dose adjustment required for CrCl <30 mL/min)
Terminal elimination half-life: 15-20 hours. Clinical context: Allows twice-daily dosing; steady-state reached in 3-5 days.
Renal: ~70% as unchanged drug and metabolites; Biliary/Fecal: ~30%
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites; <10% unchanged in feces.
Category C
Category C
Muscle Relaxant
Muscle Relaxant